SCHEMBL4437801

SCHEMBL4437801

CCN(C(=O)OC(C)(C)C)C1CCC(N)CC1

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 2/20 0.39
DPP4 P27487 2/20 0.34
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
GPR119 Q8TDV5 4/20 0.32
HSD11B1 P28845 2/20 0.32
ACHE P22303 1/20 0.31
TRPM8 Q7Z2W7 2/20 0.31
HDAC1 Q13547 1/20 0.30
HDAC2 Q92769 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
REN P00797 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3824368 0.92 CCR5 (0.42) CCR5DPP4NFKB1NFKB2RELA
SCHEMBL15236488 0.85 CCR5 (0.40) CCR5DPP4NFKB1NFKB2RELA
SCHEMBL10343966 0.85 CCR5 (0.40) CCR5DPP4NFKB1NFKB2RELA
SCHEMBL4433311 0.85 CCR5 (0.40) CCR5DPP4NFKB1NFKB2RELA
SCHEMBL8903234 0.84 DPP4 (0.33) CCR5DPP4REN
SCHEMBL8712823 0.84 DPP4 (0.33) CCR5DPP4REN
SCHEMBL8905118 0.84 DPP4 (0.33) DPP4
SCHEMBL8905115 0.84 DPP4 (0.33) DPP4
SCHEMBL25143617 0.83 CCR5 (0.41) CCR5NFKB1NFKB2RELAGPR119
SCHEMBL30201820 0.83 CCR5 (0.41) CCR5NFKB1NFKB2RELAGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2124951-A1 5-CYAN0-4- (PYRROLO Ý2, 3B¨PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2009-12-02 EP disclosed
WO-2008079346-A1 5-CYAN0-4- (PYRROLO [2, 3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-07-03 WO disclosed